CD133 mRNA when coupled with epithelial markers was able to predict colon cancer relapse and survival [7] The current study highlights the importance of CD133 mRNA as peripheral blood biomarkers for predicting imatinib sensitivity and monitoring the disease progress in the surveillance setting in GIST. Here, PROM1 is linked to malignant colon neoplasm.